<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04101760</url>
  </required_header>
  <id_info>
    <org_study_id>EOC-CSF</org_study_id>
    <nct_id>NCT04101760</nct_id>
  </id_info>
  <brief_title>Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer</brief_title>
  <official_title>Long-acting Versus Short-acting Granulocyte Colony Stimulating Factor for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Patients: A Multicenter Phase 3 Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lei Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>China-Japan Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Sixth Medical Center of PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>the Seventh Medical Center of PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to analyze the effects of long-acting versus short-acting granulocyte colony
      stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in epithelial ovarian
      cancer patients.

      Patients receive platinum-based chemotherapy of 3 to 4 weeks. Patients are randomized into
      study group and control group. In study group, patients accept long-acting G-CSF 48 hours
      from the chemotherapy. While the control group accept regular or prophylactic treatment of
      short-acting G-CSF according to National Comprehensive Cancer Network guidelines.

      The primary end is the incidence of FN in every course of chemotherapy.

      The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its
      expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF,
      quality of life, and survival outcomes (progression-free survival and overall survival).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of febrile neutropenia</measure>
    <time_frame>One year</time_frame>
    <description>Incidence of febrile neutropenia during each course of chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of myelosuppression</measure>
    <time_frame>One year</time_frame>
    <description>Incidence of febrile neutropenia during each course of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Doses of granulocyte colony stimulating factor</measure>
    <time_frame>One year</time_frame>
    <description>Doses of long-acting and short-acting granulocyte colony stimulating factor used during each course of chemotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of visits to the hospital</measure>
    <time_frame>One year</time_frame>
    <description>Visits to the outpatient clinics and emergency room</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>One years</time_frame>
    <description>Incidence of adverse events related to granulocyte colony stimulating factor according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Two years</time_frame>
    <description>Progression-free survival after the treatment of ovarian cancer during the study periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Two years</time_frame>
    <description>Overall survival after the treatment of ovarian cancer during the study periods</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chemotherapy-induced Neutropenia</condition>
  <condition>Febrile Neutropenia, Drug-Induced</condition>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Colony Stimulating Factors Adverse Reaction</condition>
  <condition>Granulocyte Colony Stimulating Factor</condition>
  <condition>Cost-effectiveness Analysis</condition>
  <condition>Quality of Life</condition>
  <condition>Progression-free Survival</condition>
  <condition>Overall Survival</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in study group accept prophylactic treatment of long-acting granulocyte colony stimulating factor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in control group accept regular or prophylactic treatment of short-acting granulocyte colony stimulating factor according to current guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long-acting granulocyte colony stimulating factor</intervention_name>
    <description>Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Short-acting granulocyte colony stimulating factor</intervention_name>
    <description>Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  With definitive pathological results of epithelial ovarian cancer

          -  With an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2

          -  Aged 18 or older

          -  Receiving 3-4 weeks per cycle of platinum-based chemotherapy with or without debulking
             surgery

          -  Regularly followed up in the study centers

          -  Provided consent for participation.

        Exclusion Criteria:

          -  Failure to meet all the inclusion criteria

          -  Non-compliance with the study protocols

          -  With a history of chemotherapy or pelvic radiotherapy for malignancies

          -  Presence of immunosuppressive diseases such as organ transplantation or acquired
             immune deficiency syndrome

          -  Treated with weekly chemotherapy regimens

          -  Presence of hematological disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lei Li, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lei Li, M.D.</last_name>
    <phone>+8613911988831</phone>
    <email>lileigh@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ming Wu, M.D.</last_name>
    <phone>+8613801224549</phone>
    <email>wuming@pumch.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lei Li</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lei Li, MD</last_name>
      <phone>008613911988831</phone>
      <email>lileigh@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>September 21, 2019</study_first_submitted>
  <study_first_submitted_qc>September 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2019</study_first_posted>
  <last_update_submitted>October 5, 2019</last_update_submitted>
  <last_update_submitted_qc>October 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Lei Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Chemotherapy-Induced Febrile Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The individual participant data will be shared as a supplement along with the published papers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

